Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Ascentage Pharma Group International ( (HK:6855) ) just unveiled an update.
Ascentage Pharma Group International has announced its upcoming Annual General Meeting (AGM) scheduled for May 19, 2025, in Suzhou, China. Key agenda items include the adoption of the company’s financial statements for 2024, re-election of several directors, and re-appointment of Ernst & Young as auditors. Additionally, the meeting will consider granting a mandate to the directors to manage share allotments, potentially impacting the company’s operational flexibility and shareholder value.
More about Ascentage Pharma Group International
Ascentage Pharma Group International is a biopharmaceutical company incorporated in the Cayman Islands. The company focuses on developing therapies for cancer, hepatitis B, and age-related diseases, with a market emphasis on innovative drug development.
YTD Price Performance: -14.19%
Average Trading Volume: 4,483,022
Technical Sentiment Signal: Strong Sell
Current Market Cap: HK$13.29B
For a thorough assessment of 6855 stock, go to TipRanks’ Stock Analysis page.